Literature DB >> 21540233

Evidence that serum levels of the soluble receptor for advanced glycation end products are inversely associated with pancreatic cancer risk: a prospective study.

Li Jiao1, Stephanie J Weinstein, Demetrius Albanes, Philip R Taylor, Barry I Graubard, Jarmo Virtamo, Rachael Z Stolzenberg-Solomon.   

Abstract

Cigarette smoking, obesity, type 2 diabetes, and, to a lesser extent, meat cooked at high temperatures are associated with pancreatic cancer. Cigarette smoke and foods cooked at higher temperatures are major environmental sources of advanced glycation end products (AGE). AGEs accumulate during hyperglycemia and elicit oxidative stress and inflammation through interaction with the receptor for AGEs (RAGE). Soluble RAGE (sRAGE) acts as an anti-inflammatory factor to neutralize AGEs and block the effects mediated by RAGE. In this study, we investigated the associations of prediagnostic measures of N(ε)-(carboxymethyl)-lysine (CML)-AGE and sRAGE with pancreatic cancer in a case-cohort study within a cohort of 29,133 Finnish male smokers. Serum samples and exposure information were collected at baseline (1985-1988). We measured CML-AGE, sRAGE, glucose, and insulin concentrations in fasting serum from 255 incident pancreatic cancer cases that arose through April 2005 and from 485 randomly sampled subcohort participants. Weighted Cox proportional hazard regression models were used to calculate relative risks (RR) and 95% CI, adjusted for age, years of smoking, and body mass index. CML-AGE and sRAGE were mutually adjusted. CML-AGE levels were not associated with pancreatic cancer [fifth compared with first quintile, RR (95% CI): 0.68 (0.38-1.22), P(trend) = 0.27]. In contrast, sRAGE levels were inversely associated with pancreatic cancer [fifth compared with first quintile, RR (95% CI): 0.46 (0.23-0.73), P(trend) = 0.002]. Further adjustment for glucose or insulin levels did not change the observed associations. Our findings suggest that sRAGE is inversely associated with pancreatic cancer risk among Finnish male smokers. ©2011 AACR

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21540233      PMCID: PMC3096705          DOI: 10.1158/0008-5472.CAN-10-2573

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  46 in total

Review 1.  Inhibitors of the Maillard reaction and AGE breakers as therapeutics for multiple diseases.

Authors:  V Prakash Reddy; Ayse Beyaz
Journal:  Drug Discov Today       Date:  2006-07       Impact factor: 7.851

Review 2.  Advanced glycation end products and insulin resistance.

Authors:  Hiroyuki Unoki; Sho-ichi Yamagishi
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

3.  Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes.

Authors:  K C B Tan; S W M Shiu; W S Chow; L Leng; R Bucala; D J Betteridge
Journal:  Diabetologia       Date:  2006-09-13       Impact factor: 10.122

4.  Tobacco smoke is a source of toxic reactive glycation products.

Authors:  C Cerami; H Founds; I Nicholl; T Mitsuhashi; D Giordano; S Vanpatten; A Lee; Y Al-Abed; H Vlassara; R Bucala; A Cerami
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-09       Impact factor: 11.205

5.  Metformin reduces endothelial cell expression of both the receptor for advanced glycation end products and lectin-like oxidized receptor 1.

Authors:  Nadjat Ouslimani; Meriem Mahrouf; Jacqueline Peynet; Dominique Bonnefont-Rousselot; Claudine Cosson; Alain Legrand; Jean-Louis Beaudeux
Journal:  Metabolism       Date:  2007-03       Impact factor: 8.694

6.  Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes.

Authors:  Kazuo Nakamura; Sho-ichi Yamagishi; Hisashi Adachi; Yayoi Kurita-Nakamura; Takanori Matsui; Takafumi Yoshida; Tsutomu Imaizumi
Journal:  Mol Med       Date:  2007 Mar-Apr       Impact factor: 6.354

7.  Antidiabetic therapies affect risk of pancreatic cancer.

Authors:  Donghui Li; Sai-Ching J Yeung; Manal M Hassan; Marina Konopleva; James L Abbruzzese
Journal:  Gastroenterology       Date:  2009-04-16       Impact factor: 22.682

8.  Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are correlated with AGEs in both diabetic and non-diabetic subjects.

Authors:  K Nakamura; S I Yamagishi; T Matsui; H Adachi; M Takeuchi; T Imaizumi
Journal:  Clin Exp Med       Date:  2008-01-11       Impact factor: 3.984

9.  Case-cohort design in practice - experiences from the MORGAM Project.

Authors:  Sangita Kulathinal; Juha Karvanen; Olli Saarela; Kari Kuulasmaa
Journal:  Epidemiol Perspect Innov       Date:  2007-12-04

Review 10.  RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation.

Authors:  Louis J Sparvero; Denise Asafu-Adjei; Rui Kang; Daolin Tang; Neilay Amin; Jaehyun Im; Ronnye Rutledge; Brenda Lin; Andrew A Amoscato; Herbert J Zeh; Michael T Lotze
Journal:  J Transl Med       Date:  2009-03-17       Impact factor: 5.531

View more
  32 in total

Review 1.  Soluble RAGEs - Prospects for treating & tracking metabolic and inflammatory disease.

Authors:  Ann Marie Schmidt
Journal:  Vascul Pharmacol       Date:  2015-06-27       Impact factor: 5.773

Review 2.  New insights into pancreatic cancer-induced paraneoplastic diabetes.

Authors:  Raghuwansh P Sah; Sajan Jiv Singh Nagpal; Debabrata Mukhopadhyay; Suresh T Chari
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-03-26       Impact factor: 46.802

3.  Circulating soluble advanced glycation end product is inversely associated with the significant risk of developing cancer: evidence from a meta-analysis.

Authors:  Lan He; Hongguang Bao; Jing Xue; Lihong Zheng; Qi Zhang; Lei Sun; Hongming Pan
Journal:  Tumour Biol       Date:  2014-05-30

4.  Dietary consumption of advanced glycation end products and pancreatic cancer in the prospective NIH-AARP Diet and Health Study.

Authors:  Li Jiao; Rachael Stolzenberg-Solomon; Thea Palmer Zimmerman; Zhigang Duan; Liang Chen; Lisa Kahle; Adam Risch; Amy F Subar; Amanda J Cross; Albert Hollenbeck; Helen Vlassara; Gary Striker; Rashmi Sinha
Journal:  Am J Clin Nutr       Date:  2014-11-19       Impact factor: 7.045

5.  Determinants of concentrations of N(ε)-carboxymethyl-lysine and soluble receptor for advanced glycation end products and their associations with risk of pancreatic cancer.

Authors:  Zhigang Duan; Guoqing Chen; Liang Chen; Rachael Stolzenberg-Solomon; Stephanie J Weinstein; Satu Mannisto; Donna L White; Demetrius Albanes; Li Jiao
Journal:  Int J Mol Epidemiol Genet       Date:  2014-10-22

6.  Serum B6 vitamers (pyridoxal 5'-phosphate, pyridoxal, and 4-pyridoxic acid) and pancreatic cancer risk: two nested case-control studies in Asian populations.

Authors:  Joyce Y Huang; Lesley M Butler; Øivind Midttun; Woon-Puay Koh; Per M Ueland; Renwei Wang; Aizhen Jin; Yu-Tang Gao; Jian-Min Yuan
Journal:  Cancer Causes Control       Date:  2016-11-09       Impact factor: 2.506

7.  Soluble receptor for advanced glycation end products and risk of liver cancer.

Authors:  Kristin A Moy; Li Jiao; Neal D Freedman; Stephanie J Weinstein; Rashmi Sinha; Jarmo Virtamo; Demetrius Albanes; Rachael Z Stolzenberg-Solomon
Journal:  Hepatology       Date:  2013-05-14       Impact factor: 17.425

8.  Predictive value of immunogenic cell death biomarkers HMGB1, sRAGE, and DNase in liver cancer patients receiving transarterial chemoembolization therapy.

Authors:  Nikolaus Kohles; Dorothea Nagel; Dietrich Jüngst; Petra Stieber; Stefan Holdenrieder
Journal:  Tumour Biol       Date:  2012-09-11

Review 9.  Epidemiology and Inherited Predisposition for Sporadic Pancreatic Adenocarcinoma.

Authors:  Rachael Z Stolzenberg-Solomon; Laufey T Amundadottir
Journal:  Hematol Oncol Clin North Am       Date:  2015-08       Impact factor: 3.722

10.  Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy.

Authors:  Oliver J Stoetzer; Debora M I Fersching; Christoph Salat; Oliver Steinkohl; Christian J Gabka; Ulrich Hamann; Michael Braun; Axel-Mario Feller; Volker Heinemann; Barbara Siegele; Dorothea Nagel; Stefan Holdenrieder
Journal:  Tumour Biol       Date:  2012-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.